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Abstract 24 
Despite the existence of effective oral therapy, tuberculosis remains a deadly 25 
pathology, namely because of bacterial resistance and incompliance with 26 
treatments. Establishing alternative therapeutic approaches is urgent and 27 
inhalable therapy has a great potential in this regard. As pathogenic bacteria are 28 
hosted by alveolar macrophages, the co-localisation of antitubercular drugs and 29 
pathogens is thus potentiated by this strategy. This work proposes inhalable 30 
therapy of pulmonary tuberculosis mediated by a single locust bean gum (LBG) 31 
formulation of microparticles associating both isoniazid and rifabutin, 32 
complying with requisites of the World Health Organisation of combined 33 
therapy. Microparticles were produced by spray-drying, at LBG/INH/RFB mass 34 
ratio of 10/1/0.5. The aerodynamic characterisation of microparticles revealed 35 
emitted doses of more than 90% and fine particle fraction of 38%, thus 36 
indicating the adequacy of the system to reach the respiratory lung area, thus 37 
partially the alveolar region. Cytotoxicity results indicate moderate toxicity (cell 38 
viability around 60%), with a concentration-dependent effect. Additionally, rat 39 
alveolar macrophages evidenced preferential capture of LBG microparticles, 40 
possibly due to chemical composition comprising mannose and galactose units 41 
that are specifically recognised by macrophage surface receptors. 42 
 43 
Keywords: inhalation, locust bean gum, microparticles, polysaccharides, spray-44 
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1. Introduction 47 
Tuberculosis (TB) remains a leading cause of death, with particular incidence 48 
and prevalence in developing countries (WHO, 2016 ). Drug resistance is a 49 
major problem, but therapeutic incompliance is also a great limitation (McBryde 50 
et al., 2017). Albeit the commercial availability of several effective oral and 51 
parenteral drugs and the existence of international treatment guidelines (NICE, 52 
2016; Wells et al., 2009), new therapeutic approaches are demanded not only to 53 
improve compliance but also to reduce the severe side effects associated with 54 
conventional therapy (Kaur et al., 2016; Lee et al., 2015). Inhalable therapy has 55 
great potential in this context, enabling the direct administration of drugs to the 56 
alveoli, where macrophages hosting pathogenic bacteria are located (Gupta et 57 
al., 2016; Parumasivam et al., 2016). 58 
In a previous work, we proposed the use of spray-dried microparticles based on 59 
locust bean gum (LBG) as inhalable formulation for the treatment of pulmonary 60 
tuberculosis. The individual association of first-line antitubercular drugs was 61 
effective and a preliminary assay further suggested high affinity of LBG 62 
microparticles for macrophages (Alves et al., 2016), which we explained by 63 
specific recognition of the mannose and galactose residues of microparticles by 64 
macrophage surface receptors (Ahsan et al., 2002). LBG was proposed in that 65 
work for the first time for lung delivery applications. It is a galactomannan and 66 
its biodegradability has been ascribed to the presence of β-mannosidase in the 67 
lung (Alkhayat et al., 1998). 68 
This work intends to produce a dry powder that delivers two antitubercular drugs 69 
upon inhalation while providing improved internalisation by macrophages, 70 
mediated by LBG. Furthermore, the respirability of LBG microparticles was 71 
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studied in order to determine their inhalability when used as carriers for 72 
antitubercular drugs. The microparticle aerosolisation profile was experimentally 73 
determined. The uptake by macrophages was assessed and compared with that of 74 
microparticles composed by a polymer devoid of specific moieties recognizable 75 
by macrophage receptors. Finally, combined therapy is proposed by the 76 
association of two first-line antitubercular drugs (isoniazid and rifabutin) in a 77 
single microparticle formulation, to meet the World Health Organisation (WHO) 78 
requirements of combined tuberculosis therapy (WHO, 2014).  79 
 80 
2. Materials and Methods 81 
2.1. Materials 82 
Locust bean gum (LBG, C30H50O26, Mw 860 kDa (Pollard et al., 2008)), poly 83 
(vinyl alcohol) (PVA, [-CH2CHOH-]n, Mw 89-98 g/mol), isoniazid (INH, 84 
C6H7N3O, Mw 137.14 g/mol), Tween 80
®, phosphate buffer saline (PBS) tablets 85 
pH 7.4, Dulbecco’s modified Eagle’s medium (DMEM), L-glutamine solution 86 
(200 mM), non-essential amino acids solution and penicillin/streptomycin 87 
(10000 units/mL, 10000 g/mL), trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L 88 
EDTA), trypan blue solution (0.4%), phorbol 12-myristate 13-acetate (PMA, 89 
C36H56O8), thiazolyl blue tetrazolium bromide (MTT), N-(3-90 
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDAC), Triton-X 91 
100, sodium dodecyl sulfate (SDS), dimethylformamide (DMF), dimethyl 92 
sulfoxide (DMSO) and HCl were purchased from Sigma-Aldrich (Germany). 93 
Lactate dehydrogenase (LDH) kit was purchased from Takara Bio (Tokyo, 94 
Japan). Rifabutin (RFB, C46H62N4O11, Mw 847.00 g/mol) was supplied by 95 
Chemos (Germany) and fetal bovine serum (FBS) by Gibco (Life Technologies, 96 
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USA). RPMI 1640 and Ham’s F12 media were obtained from Lonza Group AG 97 
(Switzerland). Ultrapure water (MilliQ, Millipore, UK) was used throughout. All 98 
other chemicals were reagent grade. 99 
 100 
2.2. Cell lines 101 
A549 cells (human alveolar epithelium) and NR8383 cells (rat alveolar 102 
macrophages) were obtained from the American Type Culture Collection 103 
(ATCC, USA) and used in passages 27-37 and 9-18, respectively. THP-1 cells 104 
(human monocytes) were obtained from the Leibniz-Institut DSMZ (Germany) 105 
and used in passages 10-20. Cell cultures were grown in humidified 5% 106 
CO2/95% atmospheric air incubator at 37 ºC (HerAcell 150, Heraeus, 107 
Germany). Cell culture medium (CCM) for A549 cells was DMEM 108 
supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine solution, 1% (v/v) 109 
non-essential amino acids solution and 1% (v/v) penicillin/streptomycin. For 110 
NR8383 cells, CCM consisted of Ham’s F12 supplemented with 15% (v/v) FBS, 111 
1% (v/v) L-glutamine and 1% (v/v) penicillin/streptomycin, while THP-1 cells 112 
were grown in RPMI 1640 medium supplemented with 10% (v/v) FBS, 1% (v/v) 113 
L-glutamine and 1% (v/v) penicillin/streptomycin. 114 
THP-1 cells were grown in suspension and cell culture was maintained between 115 
0.2 x 106 and 0.8 x 106 cells/mL. When reaching this higher concentration, cells 116 
were sub cultivated in new passage at the concentration of 0.2 x 106 cells/mL. 117 
Differentiation of THP-1 monocytes to provide the macrophage phenotype was 118 
performed using PMA (0.2 x 106 cells/mL, 50 nM, 48 hours exposure), after 119 
which the medium was replaced by fresh medium without PMA for 24 hours 120 
before the experiments. NR8383 cells grow in mixed culture (half population 121 
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keeps adherent and half suspended). Adherent cells were those used to perform 122 
the assays described below and their harvesting was made by scraping. 123 
 124 
2.3. Preparation of microparticles 125 
LBG microparticles, without drug and containing an association of the 126 
antitubercular drugs INH and RFB, were prepared by spray-drying, according to 127 
a previously reported protocol (Alves et al., 2016). The preparation of unloaded 128 
LBG microparticles involved grinding LBG in a glass mortar for 10 min, after 129 
which 5 mL HCl 0.1 M were slowly added and grinding continued until 130 
complete mixture of powder and HCl solution was obtained. This was followed 131 
by the addition of purified water previously heated to 85 ºC, up to a final volume 132 
of 50 mL. The concentration of LBG in the final solution was 2% (w/v). The 133 
solution was maintained under magnetic stirring for 30 min and subsequently 134 
placed on a water bath at 85 ºC under slow stirring for additional 30 min. At the 135 
end, the solution was kept under stirring at room temperature overnight, until the 136 
moment of spray-drying.  137 
For the production of drug-loaded microparticles, a solid dispersion of LBG and 138 
RFB was first prepared, by trituration in a mortar. After grinding, the same 139 
procedure used to prepare the LBG solution described above was applied. In 140 
parallel, INH was triturated in a mortar, being then solubilized with purified 141 
water under mild stirring for 10 minutes. The resulting solution was slowly 142 
added to the previously formed LBG/RFB solution immediately before spray-143 
drying.  144 
Microparticles were produced at LBG/INH/RFB mass ratio of 10/1/0.5 (final 145 
concentration of solids is 2.3%, w/v) using a laboratory mini spray dryer (Büchi 146 
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B-290, Büchi Labortechnik AG, Switzerland) operating in open mode and 147 
equipped with a high-performance cyclone. Protection from light was ensured 148 
for the whole process. The operating parameters were: inlet temperature: 160 ± 2 149 
ºC; aspirator setting: 85%; feed rate: 0.7 ± 0.1 mL/min; and spray flow rate: 473 150 
L/h. These conditions resulted in outlet temperature of 100 ± 2 ºC. After spray-151 
drying, microparticles were collected, placed in a dark flask and stored inside a 152 
desiccator until further use. 153 
The spray-drying yield was calculated by gravimetry, comparing the total 154 
amount of solids initially added with the resultant weight of microspheres after 155 
spray-drying (Grenha et al., 2005). 156 
Fluorescent (unloaded) microparticles of LBG or PVA were also prepared, to be 157 
used in the assay of macrophage capture. Covalent binding between fluorescein 158 
and the polymeric molecules was performed before microparticle production. To 159 
do so, LBG or PVA (1.0 g) were dissolved in HCl solution (10-4 M) at a 160 
concentration of 1% (w/v). LBG solution was applied the same treatment 161 
described above for the preparation of LBG microparticles. PVA solution was 162 
maintained at 80 ºC under stirring overnight. Fluorescein (43 mg) was dissolved 163 
in ethanol 96% (v/v) and added to the previously formed LBG or PVA solutions. 164 
EDAC (ca. 33 mg) was dissolved in milli-Q water and added to the solution. 165 
This was kept under stirring for 72 h and then dialysed (2000 Da Mw cut off) 166 
against water. Light protection was ensured in the whole process. The resulting 167 
suspension was frozen and freeze-dried (FreeZone Benchtop Freeze Dry System, 168 
Labconco, USA). The fluorescently-labelled polymers were stored in a 169 
desiccator until further use, under light protection. Fluorescent microparticles 170 
were produced by spray-drying. The used conditions were the same described 171 
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above for LBG, while the following were used for PVA: inlet temperature: 155 ± 172 
2 ºC; aspirator setting: 80%; feed rate: 1.0 ± 0.1 mL/min; and spray flow rate: 173 
473 L/h. These conditions resulted in outlet temperature of 96 ± 2 ºC.  174 
 175 
2.4. Characterisation of microparticles 176 
2.4.1. Morphology  177 
The surface morphology of LBG microparticles was characterised by field 178 
emission scanning electron microscopy (FESEM; FESEM Ultra Plus, Zeiss, 179 
Germany). Dry powders were placed onto metal plates and 5 nm thick iridium 180 
film was sputter-coated (model Q150T S/E/ES, Quorum Technologies, UK) on 181 
the samples before viewing.  182 
 183 
2.4.2. Feret’s diameter  184 
Microparticle size was estimated as the Feret’s diameter and was directly 185 
determined by optical microscopy (Microscope TR 500, VWR international, 186 
Belgium) from the manual measurement of 300 microparticles (n = 3). 187 
 188 
2.4.3. Density  189 
Real density (g/cm3) was determined using a Helium Pycnometer (Micromeritics 190 
AccuPyc 1330, Germany) (n = 3). Tap density (g/cm3) was determined using a 191 
tap density tester (Densipro 250410, Deyman, Spain), by measuring the volume 192 
of a known weight of powder before and after tapping, respectively (n = 3). The 193 
determination of tap density involved tapping the sample until no further 194 
reduction of powder volume was observed (average of 180 taps).  195 
 196 
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2.4.4. Drug association efficiency and loading  197 
The determination of microparticle drug content was performed by UV-Vis 198 
spectrophotometry (Pharmaspec UV-1700, Shimadazu, Japan), at 265.5 nm for 199 
INH and 500 nm for RFB. A screening of the matrix material (LBG) revealed no 200 
interference at the selected wavelengths.  201 
In order to determine the drug content, a certain amount of drug-loaded 202 
microparticles was incubated with HCl 0.1 M, under magnetic stirring for 60 203 
min, which ensures complete dissolution of the carriers. Samples were then 204 
centrifuged (8000 rpm, 30 min; 5810 R, Eppendorf, Germany) and filtered (0.45 205 
µm) before quantification. Calibration curves were performed at 265.5 nm for 206 
INH and at both this wavelength and at 500 nm for RFB, using the medium of 207 
dissolution of unloaded microparticles. The latter curve was used to determine 208 
the concentration of RFB and the former allowed the determination of the 209 
fraction of the absorbance at 265.5 nm that is due to RFB, the remainder being 210 
attributable to INH, thus allowing the determination of its concentration through 211 
the corresponding calibration curve. Drug association efficiency (AE) and 212 
microparticle (MP) loading capacity (LC) were estimated as follows (n = 3): 213 
AE (%) = (Real amount of drug on MP / Theoretical amount of drug on MP) x 214 
100    (Eq. 1) 215 
LC (%) = (Real amount of drug on MP/ Weight of MP) x 100  (Eq. 2) 216 
 217 
2.5. Aerodynamic characterisation of microparticles 218 
HPMC size 3 capsules (Quali-V-I, Qualicaps, Spain) were filled with 22.5 mg of 219 
LBG/INH/RFB powder. The content of four capsules was discharged in each 220 
aerodynamic test using the medium resistance RS01® inhaler (Plastiape Spa, 221 
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Italy) and experiments were performed in triplicate. The device was connected to 222 
the Andersen cascade impactor (ACI, Copley Scientific, UK) operated at 223 
60 L/min, ensuring a pressure drop of 4 kPa through the device. This was 224 
activated for 4 s in order to let 4 L of air passing through the system, thus 225 
complying with the standard procedure described by USP 38 and Ph.Eur.8 226 
(Ph.Eur., 2014; USP, 2015).  227 
ACI separates particles according to their aerodynamic diameter and it was 228 
assembled using the appropriate adaptor kit for the 60 L/min air flow test. Cut-229 
offs of the stages from -1 to 6 are the following: 8.60, 6.50, 4.40, 3.20, 1.90, 230 
1.20, 055, 0.26 µm. A glass fiber filter (Whatman, Italy) was placed right below 231 
stage 6 in order to collect particles with diameter lower than that of stage 6 cut-232 
off. 233 
The plates of the impactor were coated with a thin layer of ethanol containing 234 
1% (w/v) Tween 20 to prevent particle bounce. The drugs were recovered from 235 
the apparatus with water/acetonitrile mixture (50/50, v/v) and quantified by 236 
HPLC (Agilent 1200 series, Germany). A LiChrospher® 100 RP-18 (5 µm) 237 
column of 4 mm i.d.×250 mm length with security guard cartridge was used. 238 
The eluent was a mixture of phosphate buffer pH = 7 (A) and acetonitrile (B) at 239 
a flow rate of 1 mL/min, starting with A/B = 95:5 and kept for 5 min, followed 240 
by a 7 min step gradient, until a 20:80 A/B ratio was reached, which was then 241 
kept for 16 min. Detection was performed by a diode array detector at 275 nm. 242 
The used chromatographic conditions were: gradient flow (Phosphate buffer pH 243 
= 7 (A), acetonitrile (B); A/B from 95:5 in the first 5 min it is changed to 20:80 244 
in 7 min and kept in this 20:80 during other 16 min). A linear calibration plot for 245 
INH and RFB was obtained over the range 10-400 μg/mL (n= 3). Under these 246 
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conditions, the retention times of INH and RFB were 4.7 and 17.4 min, 247 
respectively. 248 
The quantification of drug deposited inside the impactor allows calculating 249 
different aerodynamic parameters. The emitted dose (ED) is the amount of drug 250 
ex-device, considered the total amount of drug collected in the impactor, 251 
quantified by HPLC (induction port, stages -1 to 6 and filter). The mass median 252 
aerodynamic diameter (MMAD) was determined by plotting the cumulative 253 
percentage of mass less than the stated aerodynamic diameter on probability 254 
scale versus aerodynamic diameter on logarithmic scale. The fine particle dose 255 
(FPD) corresponds to the mass of drug particles with aerodynamic diameter 256 
lower than 5 µm calculated using the particle size distribution equation obtained 257 
from the ACI analysis. The fine particle fraction (FPF) is the ratio between the 258 
FPDs and the MD. 259 
The drug recovery ranged between 77-91% in all the experiments, being thus 260 
coincident with the requisites of the pharmacopeia (Buttini et al., 2013).  261 
 262 
2.6. Determination of drug release profile 263 
The determination of drug release was performed in PBS pH 7.4 added of 1% 264 
(v/v) Tween 80®. The assay respected sink conditions, as the maximum amount 265 
of drug was always below 30% of its maximum solubility (EMA, 2014). INH 266 
solubility was considered 274 ± 4.79 mg/mL (Hiremath and Saha, 2008), while 267 
that of RFB was determined experimentally to be 0.496 mg/mL (Alves et al., 268 
2016). A determined amount of microparticles (20 mg) was incubated with the 269 
medium (10 mL), at 37 °C, under mild shaking (100 rpm, orbital shaker OS 20, 270 
Biosan, Latvia). Samples (1 mL) were periodically collected and the amount of 271 
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each drug quantified as indicated above (n = 3). Direct quantification applied for 272 
RFB, while INH required dilution (1:10). A calibration curve was performed 273 
using the medium resulting from the incubation of unloaded LBG 274 
microparticles, after centrifugation (8000 rpm, 60 min) and filtration (0.45 μm).  275 
 276 
2.7. In Vitro Biocompatibility Study 277 
2.7.1. Cell viability evaluation by MTT test 278 
The evaluation of cell viability upon exposure to LBG/INH/RFB microparticles 279 
was performed by the MTT assay, using two cell lines of high relevance within 280 
the scope of tuberculosis infection, A549 and macrophage-differentiated THP-1 281 
cells. A549 cells were seeded at a density of 1 x 104 cells/well on 96-well plates 282 
(Orange Scientific, Belgium), in 100 µL of complete DMEM. Cells were 283 
incubated for 24 h at 37 ºC in 5% CO2 atmosphere before use. THP-1 cells were 284 
differentiated with PMA to obtain the macrophage-phenotype before the 285 
experiments, according to the procedure described above, with the necessary 286 
adaptations. THP-1 cells were seeded on 96-well plates (0.035 x 106 cells/well) 287 
in 100 µL of RPMI supplemented with 50 nM of PMA and incubated for 48 h at 288 
37 ºC in 5% CO2 atmosphere. After that time, CCM was renewed for other 24 h, 289 
before the experiments. 290 
Microparticles (unloaded or drug-loaded) were exposed in the form of a 291 
suspension prepared in pre-warmed CCM without FBS and evaluated at the 292 
concentrations of 0.1 and 0.5 mg/mL (includes polymers and drugs), for 3 and 293 
24 h. INH and RFB were also tested as free drugs, at concentrations representing 294 
their loading in microparticles (0.01 and 0.05 mg/mL for INH; 0.005 and 0.025 295 
mg/mL for RFB).   296 
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MTT solution (0.5 mg/mL in PBS, pH 7.4) was added after the exposure time (in 297 
A549 cells, samples were previously removed; in THP-1 cells no removal was 298 
applied) and incubated for 2 h, after which formazan crystals were solubilised 299 
with DMSO (A549 cells) or 10% SDS in a 1:1 mixture of DMF:water (THP-1 300 
cells) and the absorbance measured by spectrophotometry (Infinite M200, 301 
Tecan, Austria). The viability of untreated cells was assumed to correspond to 302 
100% of cell viability, and viability of treated cells was compared to this control. 303 
The assay was replicated at least three times, each with six replicates.  304 
 305 
2.7.2. Determination of cell membrane integrity 306 
The integrity of cell membrane after exposure to LBG microparticles was 307 
determined by the quantification of LDH released by cells. This was performed 308 
in A549 and macrophage-differentiated THP-1 cells upon 24 h exposure to a 309 
concentration of 0.5 mg/mL of unloaded or drug-loaded LBG microparticles. 310 
The chosen concentration corresponds to the maximum concentration tested in 311 
the MTT assay. Free INH and RFB were also tested as controls (0.05 mg/mL for 312 
INH; 0.025 mg/mL for RFB). 313 
Cells were cultured in 96-well plates in the conditions described before for the 314 
MTT assay (the assays were performed simultaneously). Upon exposure, cell 315 
culture supernatants were collected, centrifuged (16 000 x g, 5 min, 4 ºC) and 316 
processed using a commercial kit. Absorbances were measured by 317 
spectrophotometry (Infinite M200, Tecan, Austria) at a wavelength of 490 nm 318 
(background correction at 690 nm).  319 
A negative control of LDH release was performed incubating cells with CCM 320 
only and Triton-X 100 (10%) was used as positive control, being assumed as 321 
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100% LDH release. Released LDH upon incubation with each sample was 322 
determined by comparison with the positive control. All measurements were 323 
performed in triplicate.  324 
 325 
2.8. Macrophage capture of LBG microparticles 326 
The determination of macrophage ability to capture microparticles was 327 
determined in vitro in two cell lines, differentiated THP-1 cells and NR8383 328 
cells. The latter were seeded (1.0 x 106 cells per well) in 6-well plates for 329 
adhered cells, with 2 mL of Ham’s F12 medium. This procedure was performed 330 
24 h before the test to ensure the adhesion of 50 to 75% of the original 331 
population. THP-1 cells (2.0 x 105 cells/mL) were suspended in RPMI medium 332 
supplemented with 50 nM PMA and seeded at 5 mL/well in 6-well plates for 333 
cells in suspension. 334 
The evaluation of microparticle uptake by macrophages was performed by flow 335 
cytometry (FacScalibur cell analyser, BD Biosciences, Belgium) upon exposure 336 
to LBG and PVA microparticles (50 µg/cm2), both fluorescently-labelled. PVA 337 
microparticles were used as control. Microparticles were aerosolised onto the 338 
macrophage layer using the Dry powder Insufflator™ (Model DP-4, Penn-339 
CenturyTM, USA) and 2 hours incubation at 37 ºC was allowed, without CCM 340 
(only a residual amount of medium was kept to ensure the hydration of cell 341 
surface). The phagocytic process was stopped by the addition of a cold solution 342 
of PBS.3% FBS (5 mL, two applications), which also provided washing. Cells 343 
were scraped and centrifuged (1500 rpm, 2 min, room temperature, centrifuge 344 
MPW – 223e, MedInstruments, Poland) in 2 mL of PBS.3% FBS. The cycle of 345 
resuspension in PBS.3% FBS and centrifugation was repeated thrice. At the end, 346 
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cells were re-suspended in 1 mL of PBS.3% FBS, transferred to cytometry tubes 347 
(BD Biosciences, Belgium) and maintained at 4 ºC until the analysis.  348 
In flow cytometry, FSC-H and SSC-H channels were used, respectively, to 349 
measure size and granularity of cells, while side scatter light was used to identify 350 
cell viable population. The amount of cells exhibiting a fluorescent signal was 351 
considered to have phagocytosed microparticles. The assay for each dose was 352 
replicated at least three times.  353 
 354 
2.9. Statistical analysis 355 
The student t-test and the one-way analysis of variance (ANOVA) with the 356 
pairwise multiple comparison procedures (Holm-Sidak method) were performed 357 
to compare two or multiple groups. For the analysis of results of in vitro release 358 
assay, a two-way ANOVA with Bonferroni’s method for multiple comparison 359 
test was used. All analysis were run using the GraphPad Prism (version 6.07) 360 
and differences were considered to be significant at a level of p < 0.05. 361 
 362 
3. Results and Discussion 363 
3.1. Preparation and characterisation of LBG/INH/RFB microparticles 364 
LBG microparticles loaded with a combination of the first-line antitubercular 365 
drugs INH and RFB were successfully obtained by spray-drying, with yields of 366 
60-70%. The used concentration of LBG (2%, w/v) was chosen from previous 367 
experiments (unpublished data) in order to provide suitable microparticle size 368 
for the purpose of lung delivery, along with acceptable spray-drying yield. 369 
Theoretical drug loadings of 8.70% (INH) and 4.35% (RFB) were selected 370 
because they provide microparticles without the formation of aggregates, in 371 
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micron-size range, which are capable to deliver the two drugs in combination. 372 
LGB was selected because of its potential to enhance macrophage uptake and the 373 
amount of polymer was kept purposely high in order to favour internalisation. 374 
The morphological observation of LBG-based microparticles, unloaded or drug-375 
loaded, revealed irregular shapes with convoluted surface (Figure 1), without 376 
any evident effect resulting from drug association. The latter was actually 377 
expected because loadings are relatively low. Similar observations on the 378 
morphology and the absence of effect of drug association were reported in a 379 
previous work with LBG microparticles associating either INH or RFB 380 
separately (Alves et al., 2016).  381 
 382 
Figure 1. Microphotographs of LBG-based microparticles viewed by scanning 383 
electron microscopy: A) Unloaded LBG microparticles; B) LBG/INH/RFB 384 
(10/1/0.5, w/w) microparticles. INH: isoniazid, LBG: locust bean gum, RFB: 385 
rifabutin. 386 
 387 
The determined Feret’s diameters were rather low, 1.35 ± 0.7 μm for unloaded 388 
LBG microparticles and 1.14 ± 0.51 μm for drug-loaded microparticles. Real 389 
densities were around 1.4 g/cm3 and tap densities varied between 0.2 and 0.37 390 
g/cm3. These values are in the same range of others reported for spray-dried 391 
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polysaccharide microparticles (Dalpiaz et al., 2015; Pai et al., 2015; Rassu et al., 392 
2015). 393 
The encapsulation of both antibiotics was very high, 94% for INH and 102% for 394 
RFB, as indicated in Table 1. The resulting loading capacities were, thus, close 395 
to theoretical maximum, being of 8.2% and 4.4% for INH and RFB, 396 
respectively. Spray-drying is a method usually reported to lead to high efficiency 397 
of drug association (Peltonen et al., 2010), as also corroborated in the present 398 
work.  Moreover, the obtained results are in line with the high association 399 
efficiencies reported for each drug when associated individually (Alves et al., 400 
2016). 401 
Table 1. Drug association efficiency and loading capacity of 402 
LBG/INH/RFB (10/1/0.5, w/w) microparticles (mean ± SD, n = 3). 403 
Drug Association efficiency (%) Loading capacity (%) 
INH 94.4 ± 3.3 8.2 ± 0.3 
RFB 102.1 ± 1.1 4.4 ± 0.1 
INH: isoniazid; RFB: rifabutin 404 
 405 
3.2. Aerodynamic behaviour of LBG/INH/RFB microparticles 406 
Considering the intended application in lung delivery, the determination of 407 
aerosolisation properties stands as the most important aspect in the design of 408 
inhalable dry powders. The in vitro aerosol performance was determined using a 409 
RS01® dry powder inhaler and the aerodynamic properties determined upon 410 
assessment in the ACI are displayed in Table 2.  411 
 412 
 413 
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Table 2. Aerodynamic characteristics of LBG/INH/RFB (10/1/0.5, w/w) 414 
microparticles (mean ± SD, n = 3). Loaded powder amount = 22.5 mg, 415 
containing 7.8 mg INH and 3.9 mg RFB, respectively. 416 
Drug Emitted dose 
(%) 
MMAD (μm) GSD (μm) FPD (mg) FPF (%) 
INH 92.6 ± 0.9 6.2 ± 0.6 2.4 ± 0.7 2.7 ± 0.6 38.0 ± 1.6          
RFB  92.0 ± 0.5 5.8 ± 0.3 2.8 ± 0.2 1.3 ± 0.1 38.1 ± 1.8 
FPD: fine particle dose; FPF: fine particle fraction; GSD: geometric standard deviation; INH: isoniazid; 417 
MMAD: mass median aerodynamic diameter; RFB: rifabutin 418 
 419 
The dose emitted from the inhaler was very satisfactory, reaching 92%. This is 420 
indicative of the favourable properties of the material LBG to produce 421 
microparticles by spray-drying with good flowing capacity. However, a 422 
consistent amount of powder impacted on the high stages of the impactor, 423 
leading to MMAD value equal to 5.8 and 6.2 μm for RFB and INH, respectively. 424 
This is due to incomplete deaggregation of microparticle clusters during the 425 
product aerosolisation. It is well known that the aerodynamic performance of a 426 
dry powder inhaler (DPI) is strongly affected by both the device and the 427 
formulation characteristics. However, the spinning movement of the capsule 428 
inside the inhaler used in this study has demonstrated to be the most efficient in 429 
powder deaggregation in comparison with other capsule-based DPI (Martinelli et 430 
al., 2015). Hence, the optimisation of microparticles, with size, shape and 431 
density promoting their aerodynamic behavior will be addressed in the future, in 432 
order to increase the amount of LBG/INH/RFB fine particles capable of reaching 433 
the target site of alveoli. Nevertheless, LBG/INH/RFB microparticles showed a 434 
FPF of 38%, indicating that 38% of the microparticles have aerodynamic 435 
diameter below 5 μm, thus having the necessary conditions to reach the 436 
respiratory zone. This value is in agreement with those usually determined for 437 
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high doses antibiotic powder formulated without lactose as carrier (Belotti et al., 438 
2015; Maretti et al., 2016).  439 
Figure 2 shows the stage-by-stage deposition profiles of both drugs encapsulated 440 
in the tested microparticles. The similarity of the profiles indicates that the two 441 
drugs were equally co-deposited on the different stages. This supports the 442 
decision of developing a carrier with drug combination, as the microparticles 443 
demonstrate to have homogeneous composition, leading to a co-deposition of 444 
drugs. 445 
 446 
Figure 2. Stage-by-stage deposition profiles of isoniazid and rifabutin inside the 447 
Andersen cascade impactor after RS01 aerosolisation at 60 L/min, inhalation 4L 448 
(values are mean ±SD, n = 3).  449 
 450 
3.3. In vitro drug release from LBG microparticles 451 
Release studies were performed in PBS pH 7.4 added of 1% Tween 80. In this 452 
way, the local pH of the alveolar zone is resembled, along with the content of 453 
surfactant (Kyle et al., 1990), and the dissolution of RFB is ensured (Alves et al., 454 
2016). The release profile determined for each drug is depicted in Figure 3.  455 
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 464 
Figure 3. In vitro release of isoniazid (INH) and rifabutin (RFB) from 465 
LBG/INH/RFB (10/1/0.5, w/w) microparticles, in PBS pH 7.4 - 1% Tween 80 466 
at 37 ºC (LBG: locust bean gum; mean ± SD, n = 3). *p < 0.05 comparing 467 
release of two drugs. 468 
 469 
As can be observed, the release of the drugs is rapid, at 30 min 40% (RFB) – 470 
50% (INH) of the antibiotics being already available. At 60 min, the values 471 
reach 73% for RFB and 84% for INH. Although the profile is very similar for 472 
both antibiotics, RFB release is somewhat slower than that of INH, with 473 
statistically significant differences at some time-points (30, 90 and 120 min, p < 474 
0.05). The higher release of INH is a consequence of its higher solubility in 475 
aqueous media (O'Neil, 2006). Considering the conditions of the assay, the rapid 476 
release was expected, as LBG is a hydrophilic polymer and rapidly dissolved, 477 
releasing the associated drugs. Despite this observation, slower drug release is 478 
expected to occur in vivo, as has been reported (Bur et al., 2010; Haghi et al., 479 
2014). When reaching the alveoli, microparticles will deposit on an epithelium 480 
* 
* 
* 
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covered by the lung lining fluid (Fröhlich et al., 2016), which is estimated to 481 
have 0.01 – 0.1 μm. In this manner, deposited particles will not be immersed, 482 
only a small part being in direct contact with fluid instead and, therefore, erosion 483 
and dissolution will initiate from underneath the microparticles (Bur et al., 2010; 484 
Haghi et al., 2014).  Ultimately, this will result in slower release and is also a 485 
relevant observation towards the objective of having particle uptake by 486 
macrophages before complete dissolution and drug release. 487 
 488 
3.4. In vitro cytotoxicity of LBG microparticles 489 
Two complementary cell viability assays were used to test the effect of 490 
LBG/INH/RFB microparticles, the metabolic assay MTT and the LDH release 491 
assay, which assesses cell membrane integrity. Considering the environment 492 
underlying tuberculosis pathogenesis, alveolar epithelial cells (A549) and 493 
macrophage-like cells (macrophage-differentiated THP-1 cells) were used. 494 
Microparticle concentrations of 0.1 and 0.5 mg/mL were tested. These are 495 
concentrations typically reported in the assessment of lung drug carriers, despite 496 
being possibly overestimated if an alveolar area of 100 m2 is considered 497 
(Fröhlich et al., 2016). Unloaded microparticles and free drugs were tested as 498 
controls.  499 
Regarding the MTT assay, as can be observed in Figure 4A and 4B, the 500 
exposure of A549 cells to drug-loaded microparticles induced very similar 501 
results after 3 h or 24 h, evidencing an absence of time-dependent effect. 502 
However, there is a clear concentration-dependent effect (p < 0.05), visible at 503 
both time-points, as the resulting cell viability decreases from 72% to 57% (at 24 504 
h) as the concentration of microparticles increases from 0.1 to 0.5 mg/mL. 505 
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Similar observations regarding the effect of time and concentration resulted from 506 
the incubation with unloaded LBG microparticles, although in that case cell 507 
viabilities remained well above the 70% considered the threshold beyond which 508 
a toxic effect is occurring (ISO, 2009). 509 
 510 
 511 
Figure 4. A549 and macrophage-like THP-1 cell viability after A) 3 h and B) 24 512 
h exposure to unloaded LBG and LBG/INH/RFB (10/1/0.5, w/w) microparticles 513 
(MP); C) 24 h exposure to INH as free drug and D) 24 h exposure to RFB as free 514 
drug. Data represent mean ± SEM (n = 3, six replicates per experiment at each 515 
concentration). Dashed line represents 70% cell viability (INH: isoniazid; LBG: 516 
locust bean gum; MP: microparticles; RFB: rifabutin). 517 
 518 
Macrophage-differentiated THP-1 cells showed a somewhat different behaviour, 519 
apparently being less sensitive to the contact with drug-loaded microparticles 520 
after short-time exposure (3 h, Figure 4A). Indeed, at that time-point, while 521 
A549 cells registered 57% cell viability for the concentration of 0.5 mg/mL, 522 
macrophage-like THP-1 cells remained at 81%. Nevertheless, the prolongation 523 
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of the exposure to 24 h (Figure 4B) decreased cell viability to 60%, which is 524 
similar to the 57% registered for A549 cells.  525 
The results obtained on both cell lines are comparable to those reported for RFB-526 
loaded LBG microparticles in a previous work and the opposite of those 527 
obtained for INH-loaded microparticles (Alves et al., 2016). This suggests that 528 
the negative effect of drug-loaded microparticles on cell viability is certainly 529 
due, at least in part, to the RFB content. The pH of microparticle suspension in 530 
cell culture medium that is incubated with cells is around 7.2, so that is not 531 
expected to have a negative contribution. As shown in Figure 4C, INH has no 532 
effect on cell viability in any of the tested conditions (concentrations, cell lines) 533 
at 24 h when exposed as free drug. An exposure of 3 h similarly generated 534 
viabilities around 90-100%, not only for INH, but also for RFB (data not 535 
shown). In turn, free RFB (Figure 4D) was observed to induce a decrease of 536 
A549 cell viability to 65% after 24 h exposure to the higher concentration, 537 
which correlates well with the results observed in the same cell line for drug-538 
loaded microparticles, although in that case viability was even lower (57%). 539 
However, a different behaviour was observed in THP-1 cells, which viability 540 
remained at 85% upon 24 h exposure to the same concentration of free RFB. 541 
Several reports on the literature indicate higher susceptibility of A549 cells 542 
comparing with THP-1 cells (Lankoff et al., 2012; Singh et al., 2015). This is 543 
generally observed in our results, where THP-1 cells frequently show higher cell 544 
viability in the same testing conditions. The fact that THP-1 cells have 85% cell 545 
viability when exposed to 0.5 mg/mL RFB and then register 60% when exposed 546 
to the same amount of antibiotic encapsulated in LBG microparticles, is possibly 547 
attributed to the phagocytic capacity of these cells (Lankoff et al., 2012). This 548 
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characteristic certainly mediates a more intense contact of the cells with RFB, 549 
leading to a reduction of cell viability (Lanone et al., 2009). As referred above 550 
for A549 cells, unloaded LBG microparticles were also tested as control in 551 
macrophage-differentiated THP-1 cells (Figure 4A and B), resulting in cell 552 
viabilities above 80% in all cases. Overall, this is a general indication on the 553 
absence of any deleterious effect of the polysaccharide on cell viability under the 554 
tested conditions. 555 
The amount of the cytoplasmic enzyme LDH released after 24 h contact with the 556 
higher concentration of microparticles and free drugs was also determined 557 
(Figure 5). The results essentially corroborate those of the MTT, with 558 
LBG/INH/RFB microparticles having the more intense effect on released LDH, 559 
which is similar in both cell lines. The incubation with CCM generated 21% 560 
LDH release in A549 cells and 38% in macrophage-differentiated THP-1 cells. 561 
The free drugs (INH and RFB) and LBG MP revealed an effect similar to that of 562 
the CCM in each cell line, with no significant differences in released LDH. On 563 
the contrary, LBG/INH/RFB microparticles induced significantly higher release 564 
of LDH in both cell lines, 58% in A549 cells and 60% in THP-1 cells (p < 0.05).  565 
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 566 
Figure 5. LDH released from A549 and macrophage-like THP-1 cells after 24 h 567 
exposure to 0.05 mg/mL isoniazid (INH), 0.025 mg/mL rifabutin (RFB), 0.5 568 
mg/mL of unloaded LBG and LBG/INH/RFB (10/1/0.5, w/w) microparticles 569 
(MP). Cells incubated with cell culture medium (CCM) are the negative control 570 
and Triton-X 100 is the positive control. Data represent mean ± SEM (n = 3, six 571 
replicates per experiment at each concentration). *p < 0.05 compared to 10% 572 
Triton X-100 573 
 574 
A comparison of results obtained from the MTT and LDH assays shows that the 575 
latter was more sensitive than the former. Drug-loaded LBG microparticles had 576 
stronger impact in released LDH (Figure 5) compared with the effect on 577 
mitochondrial dehydrogenase activity assessed in MTT assay (Figure 4B). Other 578 
studies report similar observations (Braz et al., 2017; Wang et al., 2009) and 579 
several justifications may apply. In fact, the two assays evaluate different aspects 580 
of the interaction between cells and particles. A possible explanation is that 581 
microparticles act as metabolic enhancers (Braz et al., 2017), thus accelerating 582 
MTT conversion into formazan in spite of the lower number of cells (as 583 
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indicated by the LDH assay), resulting in the overestimation of cell viability. It 584 
may also happen that the interaction occurs mostly at the plasma membrane 585 
level, causing cell lysis but without reaching intracellular mitochondria (Wang et 586 
al., 2009). The latter is however possibly not applicable at least to THP-1 cells, 587 
given the phagocytic capacity of these cells.  588 
The overall observation of cell viability results indicates that the formulation still 589 
needs some refinement to improve its toxicological profile. The results are no 590 
longer severe as those exhibited with higher amount of rifabutin (Alves et al., 591 
2016), but there is still room for improvement, perhaps by working out a 592 
solution that eliminates the use of HCl in the preparation of microparticles. 593 
Additionally, the differences observed in the two assays reinforce the need to 594 
diversify the range of tests used to obtain a more realistic view of the true impact 595 
of the envisioned application.  596 
 597 
3.5. Uptake of LBG microparticles by macrophage-like cells 598 
Considering the aim of this work, it is very important to evaluate the ability of 599 
alveolar macrophages to uptake the produced microparticles. A preliminary 600 
study evidenced an uptake around 100% of LBG microparticles independently 601 
of the tested dose (50 and 220 µg/cm2) and used cells (Alves et al., 2016). 602 
Considering this high affinity of LBG microparticles for macrophages, the 603 
lowest dose (50 µg/cm2) was selected to provide a comparison of behaviour 604 
between LBG and PVA microparticles. The latter were used as control because 605 
PVA is not reported to undergo specific recognition by macrophages. Moreover, 606 
in order to avoid interference of microparticle size in the uptake, PVA 607 
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microparticles were tailored to have size similar to LBG microparticles (Feret’s 608 
diameter was calculated as 1.5 ± 1.0 μm). 609 
As depicted in Figure 6, very high macrophage uptake (95-100%) was observed 610 
for LBG microparticles in both cell lines. In turn, PVA microparticles induced 611 
high uptake (92%) in macrophage differentiated THP-1 cells, but this value 612 
decreased significantly to 60% (p < 0.05) in rat alveolar macrophages (NR 8383 613 
cells). In that case, the uptake was significantly lower than that induced by LBG 614 
microparticles (p < 0.05), showing a higher affinity of the cells for LBG.  615 
 616 
Figure 6. Uptake of fluorescently-labelled locust bean gum (LBG) and 617 
polyvinyl alcohol (PVA) microparticles by macrophage-differentiated THP-1 618 
cells and NR8383 cells upon 2 h exposure to 50 μg microparticles/cm2, at 37 ºC. 619 
Results are expressed as mean ± SEM (n  3). 620 
 621 
Macrophages have a natural ability to uptake particulate matter (Pacheco et al., 622 
2013; Patel et al., 2015) and, thus, the uptake of a certain amount of particles 623 
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was expected in any case, independently of the particle composition. LBG is, 624 
however, a galactomannan, being composed of mannose and galactose units. 625 
These are reported to mediate favourable recognition by macrophage surface C-626 
type lectin receptors (Chavez-Santoscoy et al., 2012; Coombs et al., 2006; East 627 
and Isacke, 2002).  628 
NR8383 cells are reported to naturally express a functional mannose receptor in 629 
culture (Vigerust et al., 2012). Therefore, the different response of these cells to 630 
the two formulations of microparticles is possibly due to a higher affinity for 631 
LBG, mediated by the specific receptor recognition of LBG residues. On the 632 
contrary, THP-1 cells differentiated by PMA adopt an activation state of M0 633 
which has been reported to not express the mannose receptor (Daigneault et al., 634 
2010). The inability to differentiate between both polymers is, therefore, the 635 
possible reason for the similar capture of the two microparticle types.  636 
 637 
4. Conclusions 638 
In this work, LBG microparticles loaded with a combination of the first-line 639 
antitubercular drugs isoniazid and rifabutin were proposed as inhalable carriers 640 
for tuberculosis therapy. The co-encapsulation of the drugs in a single carrier 641 
meets WHO requirements regarding combined tuberculosis therapy. Drug 642 
release from microparticles was fast, but this is expected to be counterbalanced 643 
by the reduced amount of fluid in the alveolar zone in in vivo conditions. The 644 
experimental assessment of aerosolisation properties of LBG microparticles 645 
demonstrated a favorable respirable dose lower than 5 µm, albeit the extrafine 646 
dose potentially capable of reaching the target alveolar zone should be enhanced 647 
in order to maximise macrophage uptake. A preferential ability of rat 648 
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macrophages to uptake LBG microparticles in comparison with a control was 649 
observed in vitro, an effect attributed to the presence of mannose and galactose 650 
units in LBG. The cytotoxic evaluation of these microparticles demonstrated 651 
moderate decrease of cell viability to around 60%, indicating the need to 652 
improve this aspect. Overall, the proposed strategy of dual antibiotherapy of 653 
tuberculosis mediated by inhalable LBG microparticles is believed to be a 654 
promising approach in the treatment of the disease. 655 
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